Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

Wacker and CordenPharma are pandemic-ready

by Aayushi Pratap
June 29, 2024 | A version of this story appeared in Volume 102, Issue 20

 

A line of vials on a manufacturing line.
Credit: CordenPharma
CordenPharma and Wacker will be able to make 80 million vaccines per year.

A contract between the German government and two contract manufacturers—Wacker Chemie and CordenPharma—has been fulfilled. The partnership, formed in 2022 because of the COVID-19 vaccine shortage, is now capable of producing 80 million messenger RNA (mRNA)–based vaccines per year in short order. While Wacker will produce plasmid DNA, the starting material for mRNA vaccines, CordenPharma will make lipids for vaccine delivery and provide aseptic fill and finish and packaging.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.